Statement From the AOA Board of Trustees Regarding Proposed Florida Legislation
The American Optometric Association (AOA) will vigorously oppose any attempt to prevent Florida-licensed doctors of optometry from legally practicing at the highest levels allowed by state and federal law, including their ability to effectively communicate with their patients by introducing unnecessary confusion. The proposed legislation undermines the doctor-patient relationship that will, in turn, jeopardize patient outcomes. The AOA, in concert with the Florida Optometric Association (FOA), is tirelessly working to have SB 230 vetoed by Gov. Ron DeSantis. However, in the event this does not happen, the AOA will continue to stand side by side with the FOA and their patients. The AOA will use all means necessary to identify and defend against unjust targeting of our FOA members and the optometric profession. If necessary, the AOA is prepared to take steps up to and including legal action against any effort to discriminate against the profession of optometry or infringe on optometry’s essential and expanding role in the Florida health care system.
AOA Response to CNET EyeQue Review
With regard to your question--whether the EyeQue Vision Monitoring Kit is a good substitute for a trained professional, we can confidently say that, from a patient health and safety perspective, there is simply no replacement for an in-person comprehensive eye exam.
AOA Board of Trustees Statement Regarding C. Clayton Powell, O.D.
The Atlanta doctor of optometry and civil rights advocate fought to open doors for Black students interested in the profession, including helping to found the National Optometric Association.
American Optometric Association statement regarding CVS launch of QuickRenew
The AOA, affiliates and doctors of optometry call on CVS to acknowledge that this offering will lower the overall level of eye health care received by the public and that this test places them in the ranks of questionable vision tests apps that have and should continue to be investigated by the FDA.